Pharsight

Rybelsus is owned by Novo.

Rybelsus contains Semaglutide.

Rybelsus has a total of 8 drug patents out of which 0 drug patents have expired.

Rybelsus was authorised for market use on 20 September, 2019.

Rybelsus is available in tablet;oral dosage forms.

Rybelsus can be used as method of treating type 2 diabetes mellitus.

The generics of Rybelsus are possible to be released after 02 May, 2034.

Application	Filing Date	Opposition Party	Legal Status
EP17204363A	2020-12-04	Galenicum Health S.L.U.	Granted and Under Opposition
EP17204363A	2020-12-04	Generics (U.K.) Limited	Granted and Under Opposition
EP17204363A	2020-12-03	Hexal AG	Granted and Under Opposition
EP17204363A	2020-12-01	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP13709231A	2019-05-15	Galenicum Health S.L.U.	Granted and Under Opposition
EP13709231A	2019-05-15	Hexal AG	Granted and Under Opposition
EP13709231A	2019-05-15	Generics (U.K.) Limited	Granted and Under Opposition
EP14721834A	2019-05-15	Sanofi	Granted and Under Opposition
EP14721834A	2019-05-15	Hexal AG	Granted and Under Opposition
EP14721834A	2019-05-15	Galenicum Health S.L.U.	Granted and Under Opposition
EP14721834A	2019-05-15	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition
EP14721834A	2019-05-15	Generics (U.K.) Limited	Granted and Under Opposition
EP13709231A	2019-05-13	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP14721834A	2019-05-13	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP11805824A	2018-09-13	Generics (U.K.) Limited	Granted and Under Opposition
EP11805824A	2018-09-13	Hexal AG	Granted and Under Opposition
EP11805824A	2018-09-13	Galenicum Health S.L.	Granted and Under Opposition
EP11805824A	2018-09-12	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP06725149A	2011-05-04	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122	NOVO	Acylated GLP-1 compounds	Mar, 2026 (2 years from now)
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278123	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (8 years from now)
US11382957	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (8 years from now)
US10086047	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (8 years from now)
US10960052	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid	Dec, 2031 (8 years from now)
US10933120	NOVO	Compositions of GLP-1 peptides and preparation thereof	Mar, 2033 (9 years from now)
US10278923	NOVO	Oral dosing of GLP-1 compounds	May, 2034 (11 years from now)